SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Julong Holding Ltd. engages in the business of investment holding activities. It provides intelligent integrated solutions to public utilities, enterprises, commercial, and multifamily properties. The company was founded by Jia Qi Hu on August 07, 2023 and is headquartered in Beijing, China.

Julong Holding Ltd. - Ordinary Shares - Class A

Julong Holding Ltd. is experiencing extreme price volatility and massive volume surges, driven by retail speculation around its low float and persistent short interest. Community sentiment is sharply divided between traders aggressively chasing parabolic gains and those warning of a potential pump-and-dump scheme, with many closely monitoring for possible regulatory intervention.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing renewed attention as investors pivot toward software names, buoyed by recent analyst upgrades and optimism regarding the long-term potential of the Vector AI ad-tech platform. Despite this fundamental bullish sentiment, the stock continues to face significant volatility and choppy price action, with many in the community debating whether the current valuation reflects its growth trajectory in gaming and AI infrastructure.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is facing intense volatility following an expanded partnership announcement and a subsequent short-seller report that triggered aggressive put buying and institutional selling. While some investors see the pullback as a buying opportunity based on strong energy-to-AI fundamentals and a bolstered $25 billion Brookfield deal, others are concerned about potential supply chain bottlenecks and extended valuations.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is experiencing intense intraday volatility as traders react to contradictory reports regarding ceasefire talks with Iran, fueling speculation that algorithms are aggressively hunting stop losses. The community remains deeply divided, with many calling the price action heavily manipulated while day traders focus on scalping the violent swings and debating the impact of ongoing geopolitical headlines on market stability.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is rallying following internal reports of a transition to in-house AI chip manufacturing, coupled with the launch of its Muse Spark 1.1 model to directly challenge competitors in the AI space. The community is actively debating the sustainability of this move, with many traders focused on the technical breakout above key resistance levels while others remain skeptical of the aggressive capital expenditure required for long-term AI infrastructure.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing a significant selloff following the announcement of a new stablecoin consortium, Open USD, which is backed by major financial players. Investors are debating whether this new competition threatens Circle's market share or if the recent price decline represents an emotional overreaction and a long-term buying opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as investors focus on massive short interest, market manipulation concerns, and the high-stakes anticipation of upcoming preliminary Q2 revenue results and global expansion news. While the stock experiences daily volatility due to aggressive short-selling and sector-wide biotech fluctuations, the community remains intensely focused on potential catalysts like Anktiva sales, upcoming regulatory milestones, and strategic partnerships.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is trending as investors rotate capital from high-flying AI and semiconductor stocks into biotech, buoyed by optimism over M&A activity and regulatory flexibility. Community members are actively debating the sustainability of this sector-wide rally while closely watching clinical catalysts and index rebalancing effects on individual holdings.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is facing intense selling pressure and high volatility as investors react to macroeconomic headwinds, fueling a heated debate between retail bulls betting on long-term growth and bears capitalizing on consistent intraday price reversals. The community is sharply divided, with intense discussion around the stock's inability to hold gains, technical support levels, and the influence of institutional algorithms on recent price action.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending as investors react to a significant $550 million convertible debt offering, with many on social media debating whether the move signals institutional confidence or unnecessary dilution. While some traders are expressing frustration over the stock's long-term range-bound performance and management's capital allocation, others are actively scaling into positions, citing the potential for clinical trial readouts later in the year.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of -31.52% and -93.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four ha...

Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday

Keros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

Equity

Neutral Sentiment

Yes, I'm a buyer

Just watching

No, I'm not interested

The highly anticipated ADR listing of SK Hynix ($SKHY) goes live today. Are you a buyer of the stock? Drop your long-term thesis in the comments.

SK Hynix ($SKHY) listing day is upon us - are you a buyer? 
 
Drop a comment with your strategy.

Stocktwits

SK Hynix Inc

) listing day is upon us - are you a buyer? 
 
Drop a comment with your strategy.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KROSKeros Therapeutics Inc

Fundamentals

Latest KROS News